Subscribe to RSS
DOI: 10.1055/s-0038-1645686
Fibrin Affinity and Clearance of t-PA Deletion and Substitution Analogues
Publication History
Received 06 June 1989
Accepted after revision 12 September 1989
Publication Date:
02 July 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/199001/lookinside/thumbnails/10-1055-s-0038-1645686-1.jpg)
Summary
To investigate structure-function relationships in tissue-type plasminogen activator (t-PA) we deleted the following domains in the heavy chain: a) The epidermal growth factor domain (t-PA del. G), b) the finger domain, and the epidermal growth factor domain (t-PA del. FG), and c) the finger, the epidermal growth factor and Kr-ingle 1 (1-PA del, FGK1). To study specificly the function of the growth factor domain we made two substitutions of d) 8 amino acids (consensus sequence) in the growth factor domain (t-PA G-CS) and c) the whole domain with factor IX growth factui doniuin (t-PA G-IX). Finally, f) an analogue with substitution in the finger domain (fibronectin consensus sequence) was constructed (t-PA F-CS).
A reduced fibrin binding of all the analogues was found. The fibrin stimulated activity of all analogues was also reduced and correlated to the fibrin binding. In contrast, the activity of the analogues in the clot lysis assay and the plate assay were only slightly reduced as compared to authentic t-PA. This suggested that at high fibrin concentrations the decreased fibrin affinity was less ciitical for obtaining a high fibrinolytic activity.
All analogues had a prolonged half-life in vivo as compared to authentic t-PA. The assumption of clearance mechanism involving mainly the growth factor region (or Kringlc 1) was not challenged by the observation of a prolonged half-life for the substitution analogue t-PA F-CS.
Our results indicate that a high affinity for fibrin and rapid elimination in vivo of t-PA require a nearly intact conformation of the N-terminal part of the molecule.
-
References
- 1 Bachmann F. Plasminogen activators. In: Haemostasis and Thrombosis: Basic Principles and Clinical Practice Colman R, Hirsh J, Marder V, Salzman E. (eds). Lippincott Company; 1987. 2 318-339
- 2 Higgins DL, Vehar GA. Interaction of one-chain and two-chain tissue plasminogen activator with intact and plasmin-degraded fibrin. Biochemistry 1987; 26: 7786-7791
- 3 Tate KM, Higgins DL, Holmes WE, Winkler ME, Heyneker HL, Vehar GA. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis Biochemistry 1987; 26: 338-343
- 4 Zoller MJ, Smith M. Oligonucleotide-directed mutagenesis: a simple method using two oligonucleotide primers and a single-stranded DNA template. DNA 1984; 3 (06) 479-488
- 5 Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-462
- 6 Bradshaw HD, Parson WW, Sheffer M, Lioubin PJ, Mulvihill ER, Gordon MP. Design, construction, and use of an clcctroporator for plant protoplasts and animal cells. Analyt. Biochemistry 1987; 166: 342-348
- 7 McCracken AA, Brown JL. A filter immunoassay lor detection ol protein secreting cell colonies. Biotechniques March/April 1984; 82-87
- 8 Selmer J, Brender J, Suensen E, Thorsen S. Characterization of monochain tissue type plasminogen activator (t-PA) purified by immunoadsorption to a monoclonal antibody. In: Clinical Aspects of Fibrinolysis and Thrombolysis Jespersen J, Kluft C, Korsgaard O. (eds). South Jutland University Press; Esbjerg: 1983: 43-46
- 9 Petersen LC, Johannessen M, Foster D, Kumar A, Mulvihill E. The effect of polymerized fibrin on the catalytic activities of one-chain tissue type plasminogen activator as revealed by an analogue resistant to plasmin elenvnge. Biochim Biophys Acta 1988; 952: 245-254
- 10 Astrup T, Kok P. Assay and preparation of a tissue plasminogen activator. Methods Enzymol 1970; 19: 821-834
- 11 Brender J, Selmer J. ELISA of human tissue type plasminogen activator applying monoclonal antibody. In: Clinical Aspects of Fibrinolysis and Thrombolysis Jespersen J, Kluft C, Korsgaard U. (eds). South Jutland University Press; Esbjerg: 1983: 83-84
- 12 Philo PD, Gaffney PJ. Plasmin potency estimates: influences of the substrate used in assay. Thromb Hacmostas 1981; 45 (02) 107-109
- 13 Gaffney PJ, Templeman J, Curtis AD, Campbell PJ. The stability of tissue plasminogen activator (t-PA). Thromb Haemostas 1983; 50 (03) 650-651
- 14 Finney. Statistical Method in Biological Assay. Griffin London: 1978
- 15 Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using Bicinchoninic acid. Anal Biochem 1985; 150: 76-85
- 16 Petersen LC, Handest P, Brender J, Selmer J, JØrgensen M, Thorsen S. A Sensitive Solid-Phase Immunosorbent Assay for Tissue-Type Plasminogen Activator Activity in Plasma Using Trinitrobenzoylated Poly-D-Lysine as a Stimulator for Plasminogen Activation. Thromb Haemostas 1987; 57 (02) 205-211
- 17 Larsen GR, Henson K, Blue Y. Variants of human tissue-type plasminogen activator. J Biol Chem 1988; 263: 1023-1029
- 18 Verheijen JH, Caspers MP M, Chang GT G, de Munk GA W, Pouwels PH, Enger-Valk BE. Involvement of finger domain and Kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. Embo J 1986; 5 (13) 3525-3530
- 19 Collen D, Stassen J, Larsen G. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71: 216-219
- 20 Zonnenveld A, Veerman H, MacDonald M, Mourik J, Pannekoek H. Structure and function of human tissue-type plasminogen activator (t-PA). J Cellular Biochem 1986; 32: 169-178
- 21 Kalyan KK, Lee SG, Wilhelm J, Fu KP, Hum W, Rapaport R, Hartzell RW, Urbano C, Hung PP. Structure function analysis with tissue-type plasminogen activator. J Biol Chem 1988; 263 (06) 3971-3978
- 22 Dodd I, Nunn B, Robinson JH. Isolation, identification and pharmacokinetic properties of tissue-type plasminogen activator species: Possible localization of a clearance recognition site. Thromb Haemostas 1988; 59 (03) 523-528
- 23 Fu KP, Lee S, Hum WT, Kalyan N, Rapaport R, Hetzel R, Hung P. Disposition of a novel recombinant tissue plasminogen activator, delta 2-89 t-PA, in mice. Thromb Res 1988; 50: 33-41
- 24 Rijken DC, Emeis JJ. Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats. Biochem J 1986; 238: 643-646